MHC class I (MHC-I) molecules -termed HLA-A, HLA-B, and HLA-C in humans and H2-K, H2-D, and H2-L in mice -are highly polymorphic molecules that function to present antigenic peptides to the ␣ ␤ TCR expressed by CTLs. Maintenance of HLA polymorphism refl ects natural selection for enhanced protective immunity against the pathogens encountered by humans ( 1 ) . The MHC molecules can diff er from each other by either > 30 amino acids or only a few amino acids (micropolymorphism). This MHC-I polymorphism is generally concentrated in the antigen-binding cleft, controlling the size and diversity of the peptide repertoire presented by each HLA molecule. For instance, HLA-B44 molecules will preferentially bind peptides that possess a P2-glutamate ( 2 ) . Alleles from each of the HLA families are distributed in virtually all human populations, indicating that their maintenance refl ects an adaptable strategy for protective immunity toward diverse microbial ligands. Although it is recognized that HLA polymorphism can alter the peptide-MHC (pMHC) landscape, it remains unclear at the atomic level how HLA polymorphism directly aff ects TCR recognition.
Despite the multitude of potential pMHC landscapes, the TCR -pMHC interaction achieves remarkable specifi city, the underlying basis of which has been addressed in part by several structural and biophysical studies on the TCR -pMHC interaction ( 3 -5 ) . For example, a consensus-docking mode between the TCR and the pMHC is preserved in which the V ␣ and V ␤ domains are positioned over the ␣ 2 and ␣ 1 helices, respectively. Moreover, a recurrent theme in the such CTL clonotypes are important factors in controlling such persistent viral infections ( 15 ) .
In this paper, we have examined how this DM1 TCR interacts with the EENL determinant when bound to the three HLA-B44 allotypes. These fi ndings provide insight into the complex interactions controlling HLA-B44 restriction and reveal how micropolymorphisms can aff ect epitope conformation that subsequently fi ne tunes the responding CTL repertoire.
interactions between MHC molecules and V ␤ 8.2-TCRs has been observed ( 6, 7 ) . More globally, it is apparent that three positions (65, 69, and 155 in MHC-I) are invariably contacted by the TCR and, thus, may represent a minimal MHC restriction element ( 8 ) . However, in the mouse-based systems, the structures of TCRs ligated to H2-K b and H2-L d MHC molecules have only been reported, and in humanbased MHC-I systems, TCR co-complex structures have been limited to HLA-A2, HLA-B8, and HLA-B35 ( 3, 5 ) . Accordingly, the potential diversity as well as the possible generalities of the TCR -pMHC interaction may be underor overestimated, respectively, by the limited number of distinct HLA allotypes that have been studied. Although the H2-K b mutant system has to an extent unraveled the impact of micropolymorphism on MHC structure and function ( 9, 10 ) , it is nevertheless important to study the impact of naturally selected microvariation in HLA allotypes found in outbred human populations.
The HLA-B44 family, which comprises 60 alleles, participates in important antiviral, antitumor, and minor antigenspecifi c responses. Within this large HLA supertype, HLA-B*4402 is the predominant HLA-B44 allele in most Caucasian populations, HLA-B*4403 is the more common allele in African and Asian populations, and HLA-B*4405 is a relatively rare allotype. Although these three HLA-B44 allotypes diff er only at two positions, 116 and 156 (HLA-B*4405: 116-Tyr, 156-Asp; HLA-B*4402: 116-Asp, 156-Asp; HLA-B*4403: 116-Asp, 156-Leu), both of which are buried within the antigen-binding cleft, the impact of these micropolymorphisms on antigen presentation and TCR recognition is marked ( 11, 12 ) . For example, mismatching of HLA-B*4402 and HLA-B*4403 is associated with transplant rejection and acute graft-versus-host disease, indicating that they represent signifi cant barriers to clinical transplantation ( 13 ) . In addition, although HLA-B*4402 and HLA-B*4403 are dependent on tapasin for the loading of their peptide cargo, HLA-B*4405 is tapasin independent, and this feature engenders this allotype with a reduced susceptibility to viral evasion of immune responses ( 12 ) .
HLA-B44 + individuals recognize an immunodominant determinant (EENLLDFVRF, abbreviated to EENL) from the EBV nuclear antigen 6 (EBNA6, also called EBNA3C) ( 14 ) . This viral epitope is presented by HLA-B*4402, HLA-B*4403, and HLA-B*4405, but there is a distinct hierarchy in the CTL responses to these pMHC complexes. Namely, HLA-B*4405 + individuals respond most strongly to this determinant, and CTLs preferentially lyse target cells presenting HLA-B*4405 EENL in comparison to HLA-B*4402 EENL and HLA-B*4403 EENL targets ( 14 ) . Moreover, this preferential recognition of HLA-B*4405 EENL target cells is observed irrespective of the HLA-B44 subtype of the CTLs, or whether the EENL epitope is exogenously added or endogenously processed ( 14 ) . Interestingly, one such prototypical HLA-B*4405 EENL -restricted CTL, termed DM1 ( TRAV26-1/TRBV7-9 ), was observed to persist in an EBV-infected individual for at least 11 yr, suggesting that P10-Phe represented the main anchor residues for the Bpocket and F-pocket of HLA-B44, respectively ( 2 ), whereas the surface exposed residues P4-Leu, P6-Asp, P7-Phe, and P9-Arg represented potential TCR contact points.
Previous crystal structures of HLA-B*4402 and HLA-B*4403 in complex with a self-peptide revealed that the 156 polymorphism aff ected both the heavy chain and peptide conformation ( 11, 17 ) . However, superposition of the antigen-binding clefts of the three HLA-B44 EENL allotypes showed virtually no movement of the ␣ 1 and ␣ 2 helices (root mean square distance [r.m.s.d.] of < 0.1 and 0.2 Å , respectively), indicating that the impact of the 156 polymorphism on the pMHC landscape is peptide dependent ( Fig. 2 d ) . However, the positioning of the peptide within the antigenbinding cleft diff ered markedly between the three allotypes, and these diff erences were attributable to the interactions between the polymorphic residues at the bound peptide ( Fig. 2 d ) . The r.m.s.d. of the superposed peptides ranged from 0.4 to 0.9 Å , with the greatest movement around the mobile, centrally bulged residues of P5-Leu to P7-Phe (with an r.m.s.d. of up to 1.9 Å ). As a consequence, the peptide is positioned more closely to the ␣ 2 helix in the HLA-B* 4405 EENL structure, whereas in the HLA-B*4402 EENL structure it is positioned more closely to the ␣ 1 helix, and in HLA-B*4403 EENL it is more centrally located within the antigenbinding cleft ( Fig. 2 d ) .
In HLA-B*4403, Leu 156 formed favorable van der Waals (vdw) interactions with P5-Leu, whereas in HLA-B*4402 and HLA-B*4405, Asp 156 was observed to " push away " the P5-Leu and instead formed an H bond to the P3-Asn, and was also able to form a network of water-mediated interactions. In HLA-B*4402, the unfavorable P5-Leu -Asp 156 interaction is exacerbated by Asp 114 and the polymorphic Asp 116 , thereby creating a marked electronegative pocket at the C-terminal end of the antigen-binding cleft that is mitigated to an extent by Arg 97 ( Fig. 2 e ). In HLA-B*4405, however, position 116 is replaced by a Tyr, which will not only form more favorable interactions with the aromatic P10-Phe, namely pi -pi interactions, but will also serve to reduce the electronegative potential around the C-terminal region of the cleft ( Fig. 2 e ) . Accordingly, the diff ering hydrophobic and electrostatic properties of the antigen-binding clefts of the HLA-B44 allotypes impart diff ering conformations of the centrally bulged portion of the bound epitope (P5 -P9) that displays a more marked degree of mobility in HLA-B*4405.
HLA-B*4402 EENL , HLA-B*4403 EENL , and HLA-B*4405 EENL to 1.7, 1.6, and 2.1 Å resolution, respectively (Table S1, available at http://www.jem.org/cgi/content/full/jem.20082136/DC1). The three pMHC complexes crystallized in the same space group with isomorphous unit cells, and the bound peptide did not participate in crystal contacts. Accordingly, any conformational diff erences observed can be solely attributed to the buried polymorphic residues (positions 116 and 156) between the three allotypes. Position 116 is located at the F-pocket on the fl oor of the antigen-binding cleft, whereas position 156 is located on the ␣ 2 helix forming part of the D/E pocket on HLA-B44.
In all three HLA-B44 EENL complexes, the peptide bound in an extended conformation bulged centrally around the P6-Asp and P7-Phe. A degree of mobility in the peptide around the P6 -P7 position was evident, especially in the HLA-B*4405 EENL complex ( Fig. 2 , a -c ). As expected, P2-Glu and ND, not determined. a For cross-validation, the affi nity for the DM1 TCR -HLA-B*4405 EENL interaction was determined. This was similar irrespective of whether the DM1 TCR or the pMHC was coupled to the chip (note that the levels for the HLA-B*4402 EENL and HLA-B*4403 EENL refolds were too low to permit these MHCs to be the analytes).
nonliganded state and ligated to HLA-B*4405 EENL to a 2.75 and 3.5 Å resolution, respectively ( Fig. 4 a and Table S1 ). The data collection and structure determination of the ternary complex was challenging, as the crystal form exhibited a cell edge close to 700 Å with three complexes in the asymmetric unit. Given that we had solved the structures of the nonliganded counterparts of the ternary complex, the structure nevertheless refi ned readily at this resolution, and moreover, the electron density at the DM1 TCR -HLA-B*4405 EENL interface was unambiguous ( Fig. 4 b ) . The three complexes in the asymmetric unit were structurally identical. An overlay of the three complexes showed an overall r.m.s.d. of < 1.4 Å , where major diff erences were in the diff ering juxtapositioning of the ␤ 2 -microglobulin ( ␤ 2 m) domain (the r.m.s.d. without the ␤ 2 m domain is 0.7 Å ). Thus, unless explicitly stated, structural analysis is restricted to one complex in the asymmetric unit. The DM1 TCR docked at an angle of 80 ° across the long axis of the HLA-B*4405 EENL binding cleft, and accordingly, the DM1 TCR docked within the range of previously determined TCR -pMHC structures ( Fig. 4 c ) ( 5 ) . The DM1 TCR was essentially centrally located above HLA-B*4405 EENL and formed fi ve H bonds, eight salt bridges, and a large number of vdw interactions ( Table II ) . The total buried surface area (BSA) was ‫ف‬ 2,200 Å 2 , which lies within the range of previously determined TCR -pMHC-I structures ( 3 ) .
The V ␣ and V ␤ domains contributed roughly equally (54.6 and 45.4%, respectively) to the BSA at the HLA-B* 4405 EENL interface. Moreover, all six complementarity determining region (CDR) loops of the DM1 TCR contributed to The DM1 TCR recognizes the C-terminal end of the peptide To begin to gain an understanding of how the DM1 TCR engaged the HLA-B*4405 EENL complex, we undertook an alanine replacement scan of the epitope and assayed for CTL killing by the DM1 clone and for peptide -HLA-B*4405 binding effi ciency. As expected, mutation of the P2-Glu and P10-Phe anchor residues markedly reduced binding to HLA-B*4405 ( Fig. 3 ). Of the surface-exposed residues, substitutions at position 8 reduced T cell recognition by ‫ف‬ 10-fold, whereas substitutions at positions 6 and 9 abrogated recognition by the T cells ( Fig. 3 ). Accordingly, it appeared that the DM1 TCR focused on the P6 -P9 region of the peptide, the region that displayed the greatest variation among the three HLA-B44 EENL allotypes.
Overview of the DM1 TCR -HLA-B*4405 EENL complex
To gain a further understanding of why the DM1 TCR recognizes HLA-B*4405 EENL more eff ectively than HLA-B*4402/ 3 EENL , we determined the structure of the DM1 TCR in its the ␣ 2 helix. Accordingly, the structure of the nonliganded and ligated DM1 TCR provided insight into the large degree of plasticity that was required to enable HLA-B44 restriction.
Similar TCR usage against different HLA alleles
The DM1 TCR ( TRAV26-1*02;TRAJ13*02;TRBV7-9*01; TRBJ2-1*01;TRBD1*01 ) uses V ␣ and V ␤ gene segments similar to those of the LC13 TCR ( TRAV26-2*01;TRAJ52*01/ TRBV7-8*03;TRBJ2-7*01;TRBD1/2 ), which interacts with HLA-B*0801 bound to the FLRGRAYGL antigen ( 21 ) , as well as HLA-B44 when bound to an alloantigen. The DM1 and LC13 TCRs share similarities in the CDR1 ␣ , CDR2 ␣ , CDR1 ␤ , and CDR2 ␤ loops (for sequence conservation see Table S2 , available at http://www.jem.org/cgi/content/full/ jem.20082136/DC1) ( 22, 23 ) . In comparison to the LC13 footprint on HLA-B8 FLRGRAYGL , the CDR1 ␣ and CDR2 ␣ loops are in roughly equivalent locations, although the positioning of the corresponding loops in the V ␤ domain is more divergent ( Fig. 6 , a and b ). From examination of all known TCR -pMHC co-crystal structures, it has been noted that TCRs often use a Tyr/Phe in the CDR1 ␣ to interact with the HLA-B*4405 EENL interaction, albeit to varying degrees, which is consistent with the variable usage of CDR loops observed in TCR -pMHC-I interactions ( 3, 18 -20 ) . The CDR1 ␣ and CDR2 ␣ loops of DM1 TCR contributed 18 and 7.8%, respectively, and the CDR1 ␤ and CDR2 ␤ loops contributed 7 and 11.8%, respectively, to the BSA. In contrast, the CDR3 loops played a more prominent role, with the CDR3 ␣ and CDR3 ␤ loops contributing 19.6 and 17%, respectively, of the BSA at the DM1 TCR -HLA-B*4405 EENL interface.
Plasticity and the recognition of HLA-B44
Our fi ndings represent the fi rst report of a TCR ligated to HLA-B44 and thereby provided us with an opportunity to gain an insight into the structural requirements underscoring HLA-B44 restriction. As we determined the structure of the DM1 TCR and HLA-B*4405 EENL in the nonliganded state, we were able to address the extent of plasticity that facilitates HLA-B44 restriction. Indeed, upon ligation, the V ␣ domain of the DM1 TCR changed orientation by 6 ° relative to the V ␤ domain ( Fig. 4 d ) , in a manner analogous to that observed recently ( 20 ) , and the CDR3 ␤ loop of the DM1 TCR changed conformation appreciably upon pMHC ligation.
The DM1 TCR contacted HLA-B*4405 at positions 65, 69, and 155, three positions that have been invariably contacted in all TCR -pMHC-I structures determined to date ( 5, 8 ) , despite positions 65 and 69 representing polymorphic sites among the HLA alleles. To enable recognition, HLA-B*4405 moved minimally upon ligation (the overall r.m.s.d. was 0.45 Å ), although rearrangement of four MHC residues (Glu 65 , Glu 76 , Arg 151 , and Gln 155 ) was observed.
The CDR1 ␣ and CDR2 ␣ loops exclusively contacted residues spanning 155 -163 from the ␣ 2 helix ( Table II and Fig. 5 a ) . Asn 31 ␣ nestled in a shallow pocket that was fl anked by Leu 163 and Gln 155 , the latter of which also interacted with Tyr 33 ␣ ( Fig. 5 a ) . Interestingly, Gln 155 , previously described as a gatekeeper residue, shifted conformation upon TCR ligation to form interactions with CDR1 ␣ as well as the peptide. The CDR2 ␣ played a limited role in interacting with HLA-B44 ( Table II and Fig. 5 a ) , with Leu 57 ␣ forming vdw interactions with Glu 154 and Arg 151 , the latter of which also moved to salt bridge with framework residue Glu 67 ␣ ( Table II and Fig. 5 a ) . The CDR1 ␤ and CDR2 ␤ contacted residues spanning 69 -76 of the ␣ 1 helix ( Table II ) , with the role of CDR1 ␤ being restricted to interacting with Thr 73 and Glu 76 ( Fig. 5 b ) , a residue that moved ‫ف‬ 2.5 Å to contact the CDR1 ␤ and CDR2 ␤ loops. The CDR2 ␤ loop comprised several polar residues (Gln 57 ␤ , Asn 58 ␤ , and Glu 59 ␤ ) and, accordingly, was observed to form several H bonds to the ␣ 1 helix of HLA-B*4405 ( Fig. 5 b ) .
In addition to participating in peptide-mediated interactions, the CDR3 loops also contacted the HLA-B44 heavy chain. CDR3 ␣ made several vdw contacts with the ␣ 1 helix (residues 62 -66) that were centered on the aromatic residue Tyr 110 ␣ . Upon engagement, the CDR3 ␤ loop swung ‫ف‬ 90 ° and moved up to 5.8 Å to interact with the C terminus of the peptide (discussed in Epitope recognition by the DM1 TCR), and also formed a salt bridge between Asp 110 ␤ and Lys 146 of quite diff erent, the sandwiching of Gln 50 ␤ between Gln 72 and Glu 76 is maintained ( Fig. 6 d ) . Accordingly, there are some similarities, as well as notable diff erences, in the manner in which very similar V ␣ and V ␤ gene segments interact with diff ering pMHC landscapes.
Epitope recognition by the DM1 TCR
Although the HLA-B*4405 heavy chain did not change conformation upon DM1 TCR ligation, we observed an alteration in the conformation of the peptide (P4 -P7) upon ligation position 155 ( 24 ) . Indeed, both DM1 and LC13 use an aromatic residue to contact Gln 155 , as well as a Gly 30 ␣ to contact Ala 158 ( Fig. 6 c ) . Moreover, although CDR2 ␣ played a minor role in interacting with HLA-B44, both the DM1 TCR and the LC13 TCR use a Leu at the same position in CDR2 ␣ to conserve the interaction with Glu 154 ( Fig. 6 c ) . Although it has been suggested that a Ser in the CDR2 ␣ loop will contact the MHC at position 154 -155 ( 24 ), this has not been observed in the DM1 TCR complex or other TCR -pMHC complexes. Although the positioning of the CDR2 ␤ loops is was reminiscent of the highly specifi c interaction between the KK50.4 -HLA-E LIL interaction ( 27 ) , and is likely to be a key driver in determining the specifi city of the DM1 TCR -HLA-B*4405 EENL interaction, which is consistent with the peptide substitution data. Accordingly, the DM1 TCR made a number of critical interactions with the centrally bulged region of the epitope, which is the region that displayed the greatest degree of variability between the HLA-B*4405 EENL , HLA-B* 4402 EENL , and HLA-B*4403 EENL binary complexes.
DISCUSSION
There are ‫ف‬ 3,000 diff erent HLA alleles ( 28 ) clustered into nine HLA supertypes ( 29 ) , the maintenance of which within the human population is critical for protective immunity, disease susceptibility, autoimmunity, and drug hypersensitivity. Despite the importance of micropolymorphism in protective immunity, data are limited on how this directly relates to TCR recognition. This study provides simultaneous insight into HLA-B44 restriction, and how micropolymorphism between the HLA-B*4405, HLA-B*4403, and HLA-B*4402 ( Fig. 7 a ) analogous to the peptide " bulldozing " observed in the ELS4 TCR -HLA-B*3501 EPLP structure ( 25 ) . Upon ligation, the CDR3 ␣ loop reorientated the P4-Leu side chain, which consequently appeared to push the peptide toward the ␣ 1 helix, resulting in the complete shift of the backbone conformation of P5-Leu and P6-Asp ( Fig. 7 a ) . In addition, the side chain of P7-Phe, which was mobile in the nonliganded form ( Fig. 4 c ) , became completely ordered via interactions with the CDR3 ␤ loop. The repositioning of the peptide enabled the CDR1 ␤ , CDR3 ␣ , and CDR3 ␤ loops to interact with positions 3 -7 and 9 of the determinant. CDR1 ␤ played a major role in interacting with the peptide courtesy of some large side chains bridging the gap between the C ␣ backbones of the CDR1 ␤ loop and peptide (specifi cally, P6-Asp salt bridges to Arg 31 ␤ and the P9-Arg H bonds to Asn 30 ␤ and Arg 31 ␤ ; Fig. 7 b ) . The CDR3 ␣ loop interacted with the middle region of the peptide ( Fig. 7 b ) in which Tyr 110 ␣ and Trp 107 ␣ played a prominent role in this interaction. Tyr 110 ␣ packed against P4-Leu and Trp 107 ␣ interacted with P6-Asp and P7-Phe. Notably an analysis of the ␣ chain repertoire of HLA-B*4405 EENL -specifi c TCRs from other HLA-B*4405 + , EBVexposed individuals (Table S3 , available at http://www.jem .org/cgi/content/full/jem.20082136/DC1) revealed that this Trp is highly conserved despite this residue being encoded entirely from the N region. Furthermore, Trp is encoded by a single codon (TGG), and there is therefore a theoretically low (1 out of 64) probability of this codon appearing by coincidence ( 26 ) . This bulky Trp residue also helped to orientate the CDR3 ␤ loop, which abutted the C-terminal end of the peptide in an antiparallel manner. The main chain of Ser 112 ␤ and Tyr 113 ␤ " sat " on the P7-Phe, whereas the P9-Arg protruded into a niche formed between the CDR1 ␤ and CDR3 ␤ loops, forming an H bond to Asp 110 ␤ O ( Fig. 7 b ) . The interactions include a salt bridge between P6-Asp and Arg 107 ␤ as well as P9-Arg and Asp 110 ␤ ( Fig. 7 b ) . The cluster of charged interactions between the DM1 TCR (Arg 31 ␤ and Arg 107 ␤ ) and the peptide (P6-Asp and P9-Arg) with HLA-B35, and one each is with H2-L d and HLA-B8 ( 3 ). Accordingly, any generalities proposed could potentially be skewed toward a particular MHC allele. For example, although common pairwise interactions are observed in defi ned V ␤ 8.2 -MHC interactions ( 6, 7 ) , this generality does not extend to V ␤ 8.2 -CD1d interactions ( 31, 32 ) . The HLA-B*4405 -restricted DM1 TCR exhibits similar V ␣ and V ␤ usage to the LC13 TCR, whose cognate antigen is HLA-B8, but also alloreacts on HLA-B44 ( 33 ) . Although the respective V ␤ domains showed a large degree of variation in docking, there was some similarity in the interaction mode within the CDR1 and CDR2 loops. However, mutational mapping has shown that for the LC13 -HLA B8 FLR interaction, the energetic driving force for the interaction rested not in the CDR1 and CDR2 loops but in the CDR3 loops ( 18 ) . Perhaps the diff erent docking modes of the LC13 and DM1 TCRs may relate to a given V gene " selecting " an orientation that is specifi c for a given MHC allotype. The distinct docking modes observed may represent two examples of several potential germline-encoded modes of interaction, with each being " selected " to optimize interactions with the distinct peptides presented by the specifi c MHC allotype.
Studies on the experimental H2-K b /K bm3 system have indicated how a buried polymorphism can aff ect peptide presentation that leads to an increase in V ␤ -mediated interactions ( 10 ) . Similarly, studies in the H2-K b /K bm8 system provided some evidence to suggest that very subtle diff erences between the alleles, which may include diff ering pMHC dynamics, can aff ect TCR recognition ( 9 ) . The eff ect of buried HLA polymorphism on peptide conformation/dynamics has implications in graft-versus-host disease. Namely, donor T cells that have escaped thymic deletion caused by being weakly autoreactive toward a given pMHC may recognize very similar recipient pMHC complexes with much greater affi nity because of the changes in the peptide conformation/ dynamics. For example, the eff ect of MHC micropolymorphism on TCR recognition has been observed in comparative studies between HLA-B*3501 and HLA-B*3508. ( 34, 35 ) . Similarly, mismatching of HLA-B*4402 and HLA-B*4403, two allomorphs that diff er by just one amino acid, is a known barrier in transplantation and has been termed a " taboo mismatch " ( 13 ) . In this case, the polymorphism was shown to subtly aff ect the peptide repertoire, the conformation of the peptide, and the MHC itself ( 11 ) . Moreover, within the HLA-B*3501/B*3508 setting, it has also been established that the immunogenicity of a viral epitope is controlled by the conformation of the peptide within the antigen-binding cleft ( 36 ) , and our data resonate with these fi ndings. Such eff ects on TCR recognition of viral determinants may be an important consideration for future vaccination strategies against viruses, as markedly diff erent CTL responses to the same viral epitope may be elicited in individuals expressing closely related HLA types.
TCR degeneracy is considered to be an important factor enabling TCRs to bind a wide range of potential pMHC combinations with the limited number of T cells present in allotypes fi nely tunes the CTL response toward an EBV determinant. The micropolymorphisms between these allotypes are not accessible to the TCR, and they did not appreciably aff ect the conformation of the MHC. Nevertheless, the DM1 TCR recognized the HLA-B*4405 allotype, presenting an EBV epitope, with a 10-fold increase in affi nity when compared with HLA-B*4403 and HLA-B*4402. This is attributable to the altered conformation and dynamics of the peptide within the respective antigen-binding clefts. Specifi cally, residues 4 -7 of the EBV epitope varied between the allotypes, with the epitope displaying a greater degree of mobility in HLA-B*4405. The signifi cance of this variability and the dynamics of the epitope was apparent in the DM1 TCR -HLA-B*4405 EENL complex, whereby the DM1 TCR not only contacted this mobile region but also caused a radical reshaping of the peptide upon ligation. In addition, the slow association rates (K on ) for the DM1 TCR interaction with all three pMHC complexes are consistent with marked conformational rearrangement occurring at the TCR -pMHC interface, which further refl ects the underlying fl exibility of the TCR -pMHC interface ( 30 ) . Interestingly, the on rate for the DM1 TCR -HLA-B*4405 EENL interaction was approximately sixfold higher when compared with the interactions with HLA-B*4403 EENL and HLA-B*4402 EENL . This is consistent with the increased fl exibility of the EENL epitope in HLA-B*4405 facilitating the DM1 TCR docking, whereas the more " rigid " HLA-B*4403 EENL and HLA-B*4402 EENL complexes would be less favorable for DM1 TCR engagement.
Although structural studies have been enormously informative in addressing how the TCR can engage the pMHC, they are somewhat limited in their scope, as the subset of diff erent MHC alleles that have been solved in complex with the TCR is relatively small. For example, of the 16 unique TCR -pMHC-Ia structures that have been determined to date, seven are with H2-K b , fi ve are with HLA-A2, two are and ␤ loops start at residue number 27, the CDR2 ␣ and ␤ loops start at residue number 56, and the CDR3 ␣ and ␤ loops start at residue number 105.
The HLA-B4402/3/5 EENL crystals belonged to the space group P2 1 2 1 2 1 with unit cell dimensions (Table S1) , each consistent with one molecule in the asymmetrical unit. The structure was determined by molecular replacement using the MOLREP program with the HLA-B*4405 as the search model (available from the Protein Data Bank under accession no. 1SYV0 ) ( 11 ) . Subsequent model building was conducted using the COOT software ( 42 ) , followed by maximum-likelihood refi nement with the REFMAC 5 program ( 40, 43 ) . Refi nement was monitored by R free , and water molecules were included in the model if they were within hydrogen-bonding distance to chemically reasonable groups, and appeared in the Fo-Fc maps contoured at 3 sigma and had a B factor < 80 Å 2 .
For the DM1 TCR -HLA-B*4405 EENL complex, the data were processed and scaled using the HKL2000 software ( 38 ) . The crystals belonged to the hexagonal space group P6 5 22 with unit cell dimensions (Table S1 ), each consistent with three complexes in the asymmetrical unit. The structure was determined by molecular replacement using the PHASER program using the fully refi ned unliganded DM1 TCR and the HLA-B*4405 EENL structures (minus peptide) as search models. Subsequent minimal model building was conducted using the COOT software ( 42 ), followed by maximum-likelihood refi nement with the REFMAC 5 program ( 40, 43 ) . TLS displacement refi nement was used to model anisotropic displacements of defi ned domains. Again, the optimal TLS domains were determined using the TLS motion determination server ( 44, 45 ) and were read into the REFMAC 5 program. Tight NCS restraints were also used during the refi nement process.
All structures were validated using the PROCHECK ( 47 ) and MOL-BROBITY ( 48 ) programs. Ramachandran plots were obtained from the MOLPROBITY program ( 48 ) . The fi nal Ramachandran statistics were as follows: DM1 TCR, 92.5% (most favored region) and 98.6% (allowed region); HLA-B*4402 EENL , 97.6% (most favored region) and 100% (allowed region); HLA-B*4403 EENL , 97.9% (most favored region) and 99.5% (allowed region); HLA-B*4405 EENL , 97.1% (most favored region) and 99.2% (allowed region); and DM1 TCR -HLA-B*4405 EENL , 86.3% (most favored region) and 97.5% (allowed region). All molecular graphics representations were created using the PyMOL system ( 49 ) .
SPR measurement and analysis.
All SPR experiments were conducted at 25 ° C on the BIAcore 3000 instrument (GE Healthcare) with HBS buff er (10 mM Hepes [pH 7.4], 150 mM NaCl, and 0.005% surfactant P20). The HBS buff er was supplemented with 1% bovine serum albumin to prevent nonspecifi c binding. The human HLA-specifi c mAb, W6/32 ( 50 ) was coupled to research grade CM5 chips with standard amine coupling. For each experiment, HLA-B*4402/3/5 was passed over two fl ow cells and ‫ف‬ 200 -500 response units (RU) was captured by the antibody. The other two fl ow cells were used as control cells for each experiment. The DM1 TCR was injected over all four fl ow cells at a rate of 20 μ l/min with a concentration range of 0.39 -400 μ M. The fi nal response was calculated by subtraction of the response of the antibody alone from that of the antibody HLA-B44 complex. The antibody surface was regenerated between each analyte injection with Actisep (Sterogene). All experiments were conducted in duplicate.
For cross-validation of results, the reverse experiment was performed. The DM1 TCR was coupled to the CM5 chip using the 12H8 antibody ( 18 ) , which is conformation specifi c for a region bridging the ␣ and ␤ constant domains of the TCR. For this experiment, 400 -600 RU of the DM1 TCR was captured on the antibody, and HLA-B*4405 EENL (0.6 -150 μ M) was injected over the fl ow cells at 20 μ l/min. The total protein levels for the HLA-B* 4402 EENL and HLA-B*4403 EENL refolds were too low to permit these pMHCs to be the analytes.
BIAevaluation software (version 3.1; GE Healthcare) was used for data analysis; the 1:1 Langmuir binding model was used to calculate the kinetic constants. To allow for the capture system, the model was modifi ed to include an additional parameter for the drifting baseline for the TCR capture by 12H8. The quality of the fi t between experimental data and the binding models was evaluated by monitoring the 2 values (i.e., < 10), as well as the residual plots. the periphery. Conversely, we illustrate how a single HLA polymorphism alters the dynamics of the pMHC landscape and aff ects TCR recognition, thereby providing direct insight into the heightened specifi city of a TCR and the subtleties of TCR recognition.
MATERIALS AND METHODS
Protein expression, purifi cation, and crystallization. The DM1 TCR was expressed and purifi ed essentially as previously described ( 27 ) using an engineered disulfi de linkage in the constant domains between TRAC48 and TRBC57. In brief, the ␣ and ␤ chains of the DM1 TCR were expressed separately in Escherichia coli and purifi ed from inclusion bodies before being refolded before purifi cation. HLA-B*4402 1-276 , HLA-B*4403 1-276 , HLA-B* 4405 , and ␤ 2 m were also expressed separately in E. coli and purifi ed from inclusion bodies before being refolded before purifi cation, as previously described ( 17 ) . An excess of peptide was required to drive refolding (e.g., 45 mg of HLA-B44 heavy chain, 15 mg of ␤ 2 m, and 50 mg of peptide were mixed, resulting in ‫ف‬ 2 -3mg of pure refolded protein). Purifi ed HLA-B*4405 EENL was mixed with an excess of purifi ed DM1 TCR, and the DM1 TCR -HLA-B*4405 EENL complex was purifi ed using a gel fi ltration column (Sephadex-200; GE Healthcare). Crystals were grown by the hanging-drop, vapor-diff usion method at 20 ° C with a protein/reservoir drop ratio of 1:1.
Crystals of the DM1 TCR, the HLA-B44 peptide complexes, and the DM1 TCR -HLA-B*4405 EENL complex were all grown by the hanging-drop, vapor-diff usion method at 20 ° C with a protein/reservoir drop ratio of 1:1. The DM1 TCR was at a concentration of 10 mg/ml in TBS (10 mM Data collection, structure determination, and refi nement. The DM1 TCR crystals were frozen in liquid nitrogen using 5% glycerol as a cryoprotectant. The HLA-B*4402/03/05 EENL complexes were all frozen using 10% glycerol as the cryoprotectant. The DM1 TCR -HLA-B4405 EENL crystals were dehydrated in 25% PEG 3350 for 2 -5 min and fl ash frozen in liquid nitrogen. All data were collected on the Industrial Macromolecular Crystallography Association Collaborative Access Team beamline at the Argonne Photon Source Synchrotron using the Quantum 210 CCD detector at 100 K (ADSC). Data for the unliganded DM1 TCR and the HLA-B4402/3/5 EENL binary structures were processed using either MOSFLM ( 37 ) or HKL2000 ( 38 ) software and were scaled using SCALA software ( 39 ) from the CCP4 suite ( 40 ) or scalepack ( 38 ) .
The DM1 crystal belonged to the space group P2 1 with unit cell dimensions (Table S1 ) consistent with two molecules in the asymmetrical unit. The structure was determined by molecular replacement using the MOLREP program with the 1G4 TCR as the search model (available from the Protein Data Bank under accession no. 2BNU ) ( 41 ) . Subsequent model building was conducted using the COOT software ( 42 ), followed by maximum-likelihood refi nement with the REFMAC 5 program (CCP4 suite) ( 40, 43 ) . Translation, liberation, and screw-rotation (TLS) displacement refi nement was used to model anisotropic displacements of defi ned domains. The optimal TLS domains were determined using the TLS motion determination server ( 44, 45 ) and were read into the REFMAC 5 program. Refi nement was monitored by R free , and water molecules were included in the model if they were within hydrogen-bonding distance to chemically " reasonable " groups, and appeared in the Fo-Fc maps (where Fo and Fc are the observed and calculated structure factors, respectively) contoured at 3 sigma and had a B factor < 80 Å 2 . Tight noncrystallographic symmetry (NCS) restraints were also used during the refi nement process. The TCR was numbered according to the international ImMunoGeneTic (IMGT) unique numbering system ( 46 ) , whereby the CDR1 ␣
